KRRO logo

Korro Bio, Inc.

KRRO
Healthcare|Biotechnology|US
$14.75
+0.02 (+0.14%)
DCF Value
$9.43
Tangible Book / Share
$4.95
Cash / Share
$5.88

About

Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.

Stock Price

-54.7%(1Y)
1M
+39.4%
3M
+11.3%
6M
+22.4%
YTD
+84.1%
1Y
-54.8%
3Y
-64.4%
5Y
-95.6%

Pipeline Summary

2 total trials
2
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 1Terminated: 1

Active Trials (1)

Phase 1/2 Study of KRRO-121 in Healthy Volunteers and Patients With UCD
NCT07773246Urea Cycle Disorders, Inborn
Phase 1Phase 2Recruiting
Enrollment: 30 participants

Key Facts

Market Cap$217.2M
Employees58 (-44% YoY)
CEORam Aiyar
IPO DateOct 3, 2019
Beta2.36
52-Week Range$5.2 – $36.79
Avg Volume177,393
ExchangeNASDAQ

Ownership

Float69.7%
Shares Outstanding14.7M

Recent Insider Trades

Lynx1 Capital Management LPBUY
Oct 26, 202625,124 shares @ $11.75
Lynx1 Capital Management LPBUY
Oct 23, 20262,510 shares @ $12.11
Lynx1 Capital Management LPBUY
Oct 22, 202640,000 shares @ $11.04
Lynx1 Capital Management LPBUY
Oct 22, 202612,175 shares @ $9.68
FORMELA JEAN FRANCOISSELL
Sep 11, 20268,450 shares @ $13.99

Peers

ALTAltimmune, Inc.
$404.6M
AMRNAmarin Corporation plc
$240.1M
ANNXAnnexon, Inc.
$688.1M
ANROAlto Neuroscience, Inc.
$987.3M
AURAAura Biosciences, Inc.
$680.3M
DBVTDBV Technologies S.A.
$250.0M
ENGNenGene Holdings Inc.
$117.3M
LBRXLB Pharmaceuticals Inc Common Stock
$1.36B
Data last updated: Nov 9, 2026, 04:18 AM